174 related articles for article (PubMed ID: 28393315)
1. Identification and characterization of biomarkers and their functions for Lapatinib-resistant breast cancer.
Zhang L; Huang Y; Zhuo W; Zhu Y; Zhu B; Chen Z
Med Oncol; 2017 May; 34(5):89. PubMed ID: 28393315
[TBL] [Abstract][Full Text] [Related]
2. Identifying differentially expressed genes and screening small molecule drugs for lapatinib-resistance of breast cancer by a bioinformatics strategy.
Zhuo WL; Zhang L; Xie QC; Zhu B; Chen ZT
Asian Pac J Cancer Prev; 2014; 15(24):10847-53. PubMed ID: 25605188
[TBL] [Abstract][Full Text] [Related]
3. Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Choi JD; Kwon K; Jang CS; Ro YT; Noh YH; Kim SY
Tumour Biol; 2016 Feb; 37(2):2285-97. PubMed ID: 26361955
[TBL] [Abstract][Full Text] [Related]
4. Identification of breast cancer hub genes and analysis of prognostic values using integrated bioinformatics analysis.
Fang E; Zhang X
Cancer Biomark; 2017 Dec; 21(1):373-381. PubMed ID: 29081411
[TBL] [Abstract][Full Text] [Related]
5. Identification of prostate cancer hub genes and therapeutic agents using bioinformatics approach.
Fang E; Zhang X; Wang Q; Wang D
Cancer Biomark; 2017 Dec; 20(4):553-561. PubMed ID: 28800317
[TBL] [Abstract][Full Text] [Related]
6. Identification of differentially expressed genes regulated by molecular signature in breast cancer-associated fibroblasts by bioinformatics analysis.
Vastrad B; Vastrad C; Tengli A; Iliger S
Arch Gynecol Obstet; 2018 Jan; 297(1):161-183. PubMed ID: 29063236
[TBL] [Abstract][Full Text] [Related]
7. High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics.
Liu Z; Liang G; Tan L; Su AN; Jiang W; Gong C
Anticancer Res; 2017 Aug; 37(8):4329-4335. PubMed ID: 28739725
[TBL] [Abstract][Full Text] [Related]
8. Integrated bioinformatics analysis reveals key candidate genes and pathways in breast cancer.
Wang Y; Zhang Y; Huang Q; Li C
Mol Med Rep; 2018 Jun; 17(6):8091-8100. PubMed ID: 29693125
[TBL] [Abstract][Full Text] [Related]
9. Topological network analysis of differentially expressed genes in cancer cells with acquired gefitinib resistance.
Lee YS; Hwang SG; Kim JK; Park TH; Kim YR; Myeong HS; Kwon K; Jang CS; Noh YH; Kim SY
Cancer Genomics Proteomics; 2015; 12(3):153-66. PubMed ID: 25977174
[TBL] [Abstract][Full Text] [Related]
10. Screening and Identification of Key Biomarkers in Acquired Lapatinib-Resistant Breast Cancer.
Bao S; Chen Y; Yang F; Sun C; Yang M; Li W; Huang X; Li J; Wu H; Yin Y
Front Pharmacol; 2020; 11():577150. PubMed ID: 33013420
[TBL] [Abstract][Full Text] [Related]
11. Cross-platform meta-analysis of multiple gene expression profiles identifies novel expression signatures in acquired anthracycline-resistant breast cancer.
Lee YS; Ryu SW; Bae SJ; Park TH; Kwon K; Noh YH; Kim SY
Oncol Rep; 2015 Apr; 33(4):1985-93. PubMed ID: 25695524
[TBL] [Abstract][Full Text] [Related]
12. Discovering novel cancer bio-markers in acquired lapatinib resistance using Bayesian methods.
Azad AKM; Alyami SA
Brief Bioinform; 2021 Sep; 22(5):. PubMed ID: 33857297
[TBL] [Abstract][Full Text] [Related]
13. Gene expression changes as markers of early lapatinib response in a panel of breast cancer cell lines.
O'Neill F; Madden SF; Aherne ST; Clynes M; Crown J; Doolan P; O'Connor R
Mol Cancer; 2012 Jun; 11():41. PubMed ID: 22709873
[TBL] [Abstract][Full Text] [Related]
14. PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim.
Park SH; Ito K; Olcott W; Katsyv I; Halstead-Nussloch G; Irie HY
Breast Cancer Res; 2015 Jun; 17(1):86. PubMed ID: 26084280
[TBL] [Abstract][Full Text] [Related]
15. Lapatinib inhibits the activation of NF-κB through reducing phosphorylation of IκB-α in breast cancer cells.
Ma C; Zuo W; Wang X; Wei L; Guo Q; Song X
Oncol Rep; 2013 Feb; 29(2):812-8. PubMed ID: 23229346
[TBL] [Abstract][Full Text] [Related]
16. Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
Takeda T; Yamamoto H; Kanzaki H; Suzawa K; Yoshioka T; Tomida S; Cui X; Murali R; Namba K; Sato H; Torigoe H; Watanabe M; Shien K; Soh J; Asano H; Tsukuda K; Kitamura Y; Miyoshi S; Sendo T; Toyooka S
PLoS One; 2017; 12(2):e0171356. PubMed ID: 28158234
[TBL] [Abstract][Full Text] [Related]
17. t-Darpp overexpression in HER2-positive breast cancer confers a survival advantage in lapatinib.
Christenson JL; Denny EC; Kane SE
Oncotarget; 2015 Oct; 6(32):33134-45. PubMed ID: 26430732
[TBL] [Abstract][Full Text] [Related]
18. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
[TBL] [Abstract][Full Text] [Related]
19. Identification of biomarkers and their functions in dasatinib-resistant pancreatic cancer using bioinformatics analysis.
Wei J; Han R; Su X; Chen Y; Shi J; Cui X; Zhang H; Gong Y; Chu X; Chen J
Oncol Lett; 2019 Jul; 18(1):197-206. PubMed ID: 31289489
[TBL] [Abstract][Full Text] [Related]
20. Involvement of enhancer of zeste homolog 2 in cisplatin-resistance in ovarian cancer cells by interacting with several genes.
Wang H; Yu Y; Chen C; Wang Q; Huang T; Hong F; Zhu L
Mol Med Rep; 2015 Aug; 12(2):2503-10. PubMed ID: 25955318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
